0001193125-26-206546
SEC filingQ1 revenue accelerated 35% to $70.9M with gross profit up 47% to $52.2M, narrowing operating loss 35% to -$19.2M and net loss 33% to -$20.0M, driven by improved collections and cost discipline amid strategic investments.
Adaptive Biotechnologies delivered Q1 FY2026 results showing revenue growth of 35.1% to $70.9 million from $52.4 million in the prior year quarter. This acceleration reflects underlying business momentum, particularly in immune medicine applications where the company continues to expand clinical testing volumes through enhanced penetration in covered patient populations, new patient expansions, and payor coverage optimization. Gross profit rose 47.1% to $52.2 million, lifting the gross margin to 73.6% from the prior period. This expansion occurred as revenue gains outpaced cost increases, demonstrating operational leverage in the company's core testing and biopharma services.
Looking forward, MRD revenue is expected to increase in the short and long term through clinical volume expansion and payor optimization. However, working capital needs may rise if receivables and inventory growth outpace payables, and revenue recognition involves cumulative catch-up adjustments for revised sample estimates or canceled projects. These factors underscore execution risks in scaling while maintaining cash discipline, but the quarter's trends indicate improving financial trajectory.